{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:32:18Z","timestamp":1787927538574,"version":"build-2784847793"},"reference-count":48,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jpet.2026.104964","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:42:15Z","timestamp":1781624535000},"page":"104964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Silencing thyroid hormone receptor interactor 13\/kinetochore-associated 1 inhibits DNA damage repair and enhances Olaparib sensitivity in ovarian cancer"],"prefix":"10.1016","volume":"393","author":[{"given":"Xingzi","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"He","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiping","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Xiang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-Zi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianghui","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jpet.2026.104964_bib1","first-page":"7","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jpet.2026.104964_bib2","doi-asserted-by":"crossref","first-page":"12e.18690","DOI":"10.7717\/peerj.18690","article-title":"Identification of immunogenic cell death gene-related subtypes and risk model predicts prognosis and response to immunotherapy in ovarian cancer","volume":"12","author":"Pan","year":"2024","journal-title":"PeerJ"},{"issue":"3","key":"10.1016\/j.jpet.2026.104964_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/his.13248","article-title":"High-grade serous carcinoma of tubo-ovarian origin: recent developments","volume":"71","author":"Singh","year":"2017","journal-title":"Histopathology"},{"key":"10.1016\/j.jpet.2026.104964_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001136","article-title":"CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer","volume":"9","author":"Yang","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.jpet.2026.104964_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.3892\/or.2022.8293","article-title":"Molecular mechanisms of platinum-based chemotherapy resistance in ovarian cancer (Review)","volume":"47","author":"Yang","year":"2022","journal-title":"Oncol Rep"},{"issue":"6","key":"10.1016\/j.jpet.2026.104964_bib6","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1007\/s11523-021-00842-1","article-title":"Olaparib: a review as first-line maintenance therapy in advanced ovarian cancer","volume":"16","author":"Paik","year":"2021","journal-title":"Target Oncol"},{"issue":"10","key":"10.1016\/j.jpet.2026.104964_bib7","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.annonc.2022.06.011","article-title":"Efficacy of subsequent chemotherapy for patients with BRCA1\/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2\/ENGOT Ov-21 trial","volume":"33","author":"Frenel","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.jpet.2026.104964_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.14162","article-title":"Association of copy number variation signature and survival in patients with serous ovarian cancer","volume":"4","author":"Graf","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jpet.2026.104964_bib9","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.4103\/ijc.IJC_53_21","article-title":"A review on mechanisms of resistance to PARP inhibitors","volume":"59","author":"Desai","year":"2022","journal-title":"Indian J Cancer"},{"issue":"4","key":"10.1016\/j.jpet.2026.104964_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/narcan\/zcac042","article-title":"Mechanisms of PARP1 inhibitor resistance and their implications for cancer treatment","volume":"4","author":"Jackson","year":"2022","journal-title":"NAR Cancer"},{"issue":"1","key":"10.1016\/j.jpet.2026.104964_bib11","doi-asserted-by":"crossref","first-page":"5065","DOI":"10.1038\/s41467-019-12836-9","article-title":"AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity","volume":"10","author":"Fok","year":"2019","journal-title":"Nat Commun"},{"issue":"6835","key":"10.1016\/j.jpet.2026.104964_bib12","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/35077213","article-title":"Proliferation, cell cycle and apoptosis in cancer","volume":"411","author":"Evan","year":"2001","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.jpet.2026.104964_bib13","doi-asserted-by":"crossref","first-page":"R966","DOI":"10.1016\/j.cub.2012.10.006","article-title":"The spindle assembly checkpoint","volume":"22","author":"Lara-Gonzalez","year":"2012","journal-title":"Curr Biol"},{"issue":"6","key":"10.1016\/j.jpet.2026.104964_bib14","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s13205-021-02800-0","article-title":"KNTC1 knockdown suppresses cell proliferation of colon cancer","volume":"11","author":"Zhengxiang","year":"2021","journal-title":"3 Biotech"},{"issue":"12","key":"10.1016\/j.jpet.2026.104964_bib15","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/35046598","article-title":"Human Zw10 and ROD are mitotic checkpoint proteins that bind to kinetochores","volume":"2","author":"Chan","year":"2000","journal-title":"Nat Cell Biol"},{"issue":"11","key":"10.1016\/j.jpet.2026.104964_bib16","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nrm3888","article-title":"Signalling dynamics in the spindle checkpoint response","volume":"15","author":"London","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"33","key":"10.1016\/j.jpet.2026.104964_bib17","doi-asserted-by":"crossref","first-page":"12019","DOI":"10.1073\/pnas.1412901111","article-title":"Disassembly of mitotic checkpoint complexes by the joint action of the AAA-ATPase TRIP13 and p31(comet)","volume":"111","author":"Eytan","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.jpet.2026.104964_bib18","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13046-026-03651-4","article-title":"KNTC1 initiates a KNTC1\/E2F8\/MYC positive feedback loop to facilitate tumorigenesis and enhance chemoresistance in bladder cancer","volume":"45","author":"Chen","year":"2026","journal-title":"J Exp Clin Cancer Res"},{"issue":"Pt 1","key":"10.1016\/j.jpet.2026.104964_bib19","article-title":"KNTC1 functions as a potential biomarker and oncogene regulating proliferation, migration and apoptosis in gastric cancer","volume":"143","author":"Qi","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"8","key":"10.1016\/j.jpet.2026.104964_bib20","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1002\/mc.23748","article-title":"KNTC1 knockdown inhibits the proliferation and migration of osteosarcoma cells by MCM2","volume":"63","author":"Zhong","year":"2024","journal-title":"Mol Carcinog"},{"issue":"7","key":"10.1016\/j.jpet.2026.104964_bib21","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.7150\/ijbs.32718","article-title":"Increased expression of TRIP13 drives the tumorigenesis of bladder cancer in association with the EGFR signaling pathway","volume":"15","author":"Gao","year":"2019","journal-title":"Int J Biol Sci"},{"issue":"8","key":"10.1016\/j.jpet.2026.104964_bib22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41419-024-07012-x","article-title":"TRIP13 regulates progression of gastric cancer through stabilising the expression of DDX21","volume":"15","author":"Zhang","year":"2024","journal-title":"Cell Death Dis"},{"issue":"1","key":"10.1016\/j.jpet.2026.104964_bib23","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1007\/s11033-024-10012-x","article-title":"Role of TRIP13 in human cancer development","volume":"51","author":"Chen","year":"2024","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.jpet.2026.104964_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2024.110958","article-title":"CRABP2 reduces the sensitivity of olaparib in ovarian cancer by downregulating caspase-8 and decreasing the production of reactive oxygen species","volume":"393","author":"Zeng","year":"2024","journal-title":"Chem Biol Interact"},{"issue":"11","key":"10.1016\/j.jpet.2026.104964_bib25","doi-asserted-by":"crossref","first-page":"3468","DOI":"10.3390\/cancers12113468","article-title":"Tumor BRCA testing in high grade serous carcinoma: mutation rates and optimal tissue requirements","volume":"12","author":"Turashvili","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"14","key":"10.1016\/j.jpet.2026.104964_bib26","doi-asserted-by":"crossref","first-page":"11488","DOI":"10.1021\/acs.jmedchem.4c00113","article-title":"New horizons of synthetic lethality in cancer: current development and future perspectives","volume":"67","author":"Previtali","year":"2024","journal-title":"J Med Chem"},{"issue":"10","key":"10.1016\/j.jpet.2026.104964_bib27","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/mc.23064","article-title":"Activation of Wnt signaling promotes olaparib resistant ovarian cancer","volume":"58","author":"Yamamoto","year":"2019","journal-title":"Mol Carcinog"},{"issue":"1","key":"10.1016\/j.jpet.2026.104964_bib28","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3892\/ijo.2022.5379","article-title":"Exposure to escalating olaparib does not induce acquired resistance to PARPi and to other chemotherapeutic compounds in ovarian cancer cell lines","volume":"61","author":"Fedier","year":"2022","journal-title":"Int J Oncol"},{"issue":"10","key":"10.1016\/j.jpet.2026.104964_bib29","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/0008-5472.CAN-20-2912","article-title":"Heterogeneity and clonal evolution of acquired PARP inhibitor resistance in TP53- and BRCA1-deficient cells","volume":"81","author":"F\u00e4rkkil\u00e4","year":"2021","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.jpet.2026.104964_bib30","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ygyno.2022.10.011","article-title":"Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance","volume":"167","author":"Cheng","year":"2022","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jpet.2026.104964_bib31","article-title":"TRIP13 identified by WGCNA as a progression-related and prognostic biomarker in ovarian cancer","volume":"13","author":"Zhang","year":"2026","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jpet.2026.104964_bib32","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1007\/s00432-022-04146-3","article-title":"KNTC1 as a putative tumor oncogene in pancreatic cancer","volume":"149","author":"Liu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.jpet.2026.104964_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110498","article-title":"Silencing of KNTC1 inhibits hepatocellular carcinoma cells progression via suppressing PI3K\/Akt pathway","volume":"101","author":"Tong","year":"2023","journal-title":"Cell Signal"},{"key":"10.1016\/j.jpet.2026.104964_bib34","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1016\/j.csbj.2019.06.005","article-title":"Insights into a crucial role of TRIP13 in human cancer","volume":"17","author":"Lu","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"issue":"2","key":"10.1016\/j.jpet.2026.104964_bib35","first-page":"304","article-title":"Mechanisms of chemotherapy resistance in ovarian cancer","volume":"5","author":"Ortiz","year":"2022","journal-title":"Cancer Drug Resist"},{"issue":"21","key":"10.1016\/j.jpet.2026.104964_bib36","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","article-title":"Trapping of PARP1 and PARP2 by clinical PARP inhibitors","volume":"72","author":"Murai","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpet.2026.104964_bib37","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.2147\/OTT.S272199","article-title":"Ovarian cancer therapy: homologous recombination deficiency as a predictive biomarker of response to PARP inhibitors","volume":"15","author":"Miller","year":"2022","journal-title":"Onco Targets Ther"},{"issue":"1","key":"10.1016\/j.jpet.2026.104964_bib38","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41573-024-01060-w","article-title":"DNA damage response inhibitors in cancer therapy: lessons from the past, current status and future implications","volume":"24","author":"Drew","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"31","key":"10.1016\/j.jpet.2026.104964_bib39","article-title":"KLF5 promotes tumor progression and PARP inhibitor resistance in ovarian cancer","volume":"10","author":"Wu","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.jpet.2026.104964_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217505","article-title":"ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombination","volume":"613","author":"Li","year":"2025","journal-title":"Cancer Lett"},{"issue":"12","key":"10.1016\/j.jpet.2026.104964_bib41","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.3390\/genes13122390","article-title":"53BP1: keeping it under control, even at a distance from DNA damage","volume":"13","author":"Rass","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.jpet.2026.104964_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.mrrev.2014.06.002","article-title":"The Ku heterodimer: function in DNA repair and beyond","volume":"763","author":"Fell","year":"2015","journal-title":"Mutat Res Rev Mutat Res"},{"key":"10.1016\/j.jpet.2026.104964_bib43","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1038\/ncomms5527","article-title":"TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer","volume":"5","author":"Banerjee","year":"2014","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jpet.2026.104964_bib44","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/s13578-023-01117-0","article-title":"MRE11:p.K464R mutation mediates olaparib resistance by enhancing DNA damage repair in HGSOC","volume":"13","author":"Zhuang","year":"2023","journal-title":"Cell Biosci"},{"issue":"1","key":"10.1016\/j.jpet.2026.104964_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2024.114036","article-title":"Inactivation of VRK1 sensitizes ovarian cancer to PARP inhibition through regulating DNA-PK stability","volume":"438","author":"Kim","year":"2024","journal-title":"Exp Cell Res"},{"issue":"7","key":"10.1016\/j.jpet.2026.104964_bib46","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/s41556-023-01165-1","article-title":"Transmembrane nuclease NUMEN\/ENDOD1 regulates DNA repair pathway choice at the nuclear periphery","volume":"25","author":"Chen","year":"2023","journal-title":"Nat Cell Biol"},{"issue":"1","key":"10.1016\/j.jpet.2026.104964_bib47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s42003-022-03363-3","article-title":"Polarity protein SCRIB interacts with SLC3A2 to regulate proliferation and tamoxifen resistance in ER+ breast cancer","volume":"5","author":"Saito","year":"2022","journal-title":"Commun Biol"},{"issue":"2","key":"10.1016\/j.jpet.2026.104964_bib48","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/sj.cr.7310145","article-title":"Cell polarity protein Par3 complexes with DNA-PK via Ku70 and regulates DNA double-strand break repair","volume":"17","author":"Fang","year":"2007","journal-title":"Cell Res"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356526011638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T14:11:09Z","timestamp":1787926269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356526011638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0022356526011638"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104964","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Silencing thyroid hormone receptor interactor 13\/kinetochore-associated 1 inhibits DNA damage repair and enhances Olaparib sensitivity in ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2026.104964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104964"}}